Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | HRH1 | P35367 | 3/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | CASR | P41180 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11796932 | 0.89 | KCNH2 (0.76) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| Hydrochloric Acid SCHEMBL11794831 | 0.87 | KCNH2 (0.73) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| SCHEMBL3643077 | 0.86 | HTR2A (0.59) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| SCHEMBL3637324 | 0.83 | KCNH2 (0.63) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| SCHEMBL10045128 | 0.83 | KCNH2 (0.75) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| SCHEMBL5999515 | 0.81 | HRH1 (0.63) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| SCHEMBL10045156 | 0.81 | KCNH2 (0.72) | KCNH2HTR2AHRH1SIGMAR1KDM1A | |
| SCHEMBL10045174 | 0.81 | KCNH2 (0.72) | KCNH2HTR2AHRH1SIGMAR1KDM1A | |
| SCHEMBL6665484 | 0.80 | HTR2A (0.57) | KCNH2HTR2AHRH1OPRM1CYP3A4 | |
| SCHEMBL3644776 | 0.80 | HRH1 (0.54) | KCNH2HTR2AHRH1OPRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743853-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMA INC (US) | 2001-05-02 | — | — | EP | claimed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| JP-2004002437-A | COMPOUND ACTIVE AT NEW POSITION ON RECEPTOR-OPERATED CALCIUM CHANNEL USEFUL FOR TREATING NEUROPRAXIA AND NEUROPATHY | NPS PHARMACEUT INC | 2004-01-08 | — | — | JP | disclosed |
| EP-0743853-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMA INC (US) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | KCNH2 1249/4885HTR2A 282/4885HRH1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.